BRAF and melanoma: Indeed, BRAF and MEK co-inhibition has been shown to counteract the immunosuppressive function of the oncogenic mutant BRAF V600E and to enhance adoptive cell transfer immunotherapy in a mouse model of BRAF V600E-driven melanoma (28).